Evidence supporting the use of: Cannabidiolic acid
For the health condition: Epilepsy

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidiolic acid (CBDA) is a precursor to cannabidiol (CBD) and is found in raw cannabis plants. While there is robust scientific evidence supporting the use of CBD (not CBDA) for certain forms of epilepsy—particularly Dravet syndrome and Lennox-Gastaut syndrome—CBDA itself is much less studied. The anticonvulsant properties of CBDA have been investigated primarily in preclinical studies, including animal models, where some antiepileptic effects have been observed. However, there are currently no large-scale clinical trials, regulatory approvals, or consensus medical guidelines supporting the use of CBDA for epilepsy in humans.

Most scientific evidence and clinical use in epilepsy focus on CBD, which has been approved in pharmaceutical form (Epidiolex) for treatment-resistant epilepsy. CBDA has a different pharmacological profile, and research suggests it may interact with serotonin receptors and other pathways, but its efficacy and safety in epilepsy remain unproven. Thus, while there is some emerging scientific interest and preliminary data from animal studies, CBDA cannot be considered an evidence-based treatment for epilepsy at this time. Its use is not traditional for this condition, and the scientific support is currently weak, meriting a low rating.

More about Cannabidiolic acid
More about Epilepsy

Other health conditions supported by Cannabidiolic acid

Epilepsy
Inflammation
Pain (general remedies for)
Seizures

Products containing Cannabidiolic acid

We currently have no products on Vitabase that contain this ingredient.